

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 498 143 A1**

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
19.01.2005 Bulletin 2005/03

(51) Int Cl.7: **A61K 47/44**, A61K 9/107,
A61K 47/14, A61K 31/337

(21) Application number: **03291798.1**

(22) Date of filing: **18.07.2003**

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
AL LT LV MK

(71) Applicant: **Aventis Pharma S.A.**
92160 Antony (FR)

(72) Inventors:
• **Peracchia, Maria-Teresa**
75005 Paris (FR)

• **Cote, Sophie**
92160 Antony (FR)
• **Gaudel, Gilbert**
75013 Paris (FR)

(74) Representative: **Le Pennec, Magali et al**
Aventis Pharma S.A.
Direction des Brevets,
Tri LEO/144
20, Avenue Raymond Aron
92165 Antony Cedex (FR)

(54) **Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids**


(57) Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids. The present invention relates to novel formulations of taxoids for oral administration.

EP 1 498 143 A1

Description

[0001] The present invention relates to oral formulations of taxoids.

[0002] The taxoids used in the formulations according to the invention are preferably of the general formula (I)



wherein

R_1 is H, acyl (C_2-C_4), alkyl (C_1-C_3),

R_2 is OH, alkoxy or R_2 and R_3 are methylene,

R_3 is CH_3 or R_2 and R_3 are methylene,


R_4 is $OCOCH_3$ or $OCOOCH_3$,

R is phenyl or alkoxy (C_3-C_4) or alkenyloxy (C_3-C_4), preferably phenyl or tert-butoxy,


R' is aryl, preferably phenyl, optionally substituted or alkyl (C_2-C_4) or alkenyl (C_2-C_4).

[0003] The taxoids used in the formulations according to the invention are for example the taxoids of formula (Ia) to (If) below


Formula Ia: (Docetaxel)




Formula Ib:




Formula Ic:




Formula Id: (Paclitaxel)



Formula Ic:



Formula If:



[0004] Taxoids of general formula (Ia) to (If) and their applications are known. These taxoids are particularly advantageous for their use as chemotherapeutic agents. Unfortunately, taxoids are poorly water-soluble compounds. The molecules are slightly lipophilic with a relatively high molecular weight. Up until now taxoids are administered intravenously, in particular using formulations consisting of PS80 or cremophor at high content. It was the aim of the current invention to develop taxoid formulations for oral administration.

[0005] Oral administration of PS80 or cremophor formulations of taxoids led to an extremely low bioavailability in animals probably because of a high metabolism rate, like e.g. dogs. In addition, formulations consisting of a high content of PS80 (e.g. less than 40 mg taxoid/g PS80) are not desirable for oral administration because of the potential toxicity of PS80 in contact with the intestinal mucosa. Furthermore, a dose escalation study would not be possible with the expected doses because of the solubility limit and as a consequence the limited PS80 solubilisation capacity for taxoids in gastro-intestinal fluids. Finally, the pharmaceutical development of a drug dosage form would be a main issue: indeed, the extemporary dilution of the PS80 solution with an aqueous medium is not envisageable for the oral administration of a cytotoxic agent.

[0006] Numerous documents describe systems suitable for solubilising and/or enhancing the bioavailability of hydrophobic active ingredients. However, the systems tested have so far proved ineffective for the preparation of pharmaceutical compositions containing taxoids which are stable and bioavailable and in which the taxoid can be administered orally at an effective concentration.

[0007] WO 95/24893 describes delivery systems for hydrophobic drugs. This application describes compositions comprising a digestible oil, a lipophilic surfactant and a hydrophilic surfactant that are intended for the formulation of hydrophobic active ingredients and for the enhancement of their bioavailability.

[0008] WO 99/49848 describes pharmaceutical dosage forms for anticancer drugs, e.g. paclitaxel in which the active drug is formulated as stable self-emulsifying concentrate. WO 99/49848 describes compositions comprising an anticancer drug in a carrier system comprising at least one hydrophobic component selected from tri-, di- or monoglyc-

erides, free fatty acids, fatty acid esters or derivatives thereof, and a hydrophilic component selected from hydroxyalkane, dihydroxyalkane or polyethylene glycol (PEG), and comprising at least one surfactant.

[0009] EP 0 152 945 B1 describes transparent multi-component systems for pharmaceutical application containing one or several active ingredients in a system composed of an oil component, surfactants, co-surfactant and optionally water.

[0010] EP 0 670 715 B1 describes compositions for pharmaceutical use intended to be ingested, able to form a microemulsion, comprising at least an active ingredient, a lipophilic phase, a surfactant, a co-surfactant and a hydrophilic phase of special composition.

[0011] EP 0 334 777 B1 describes a micro-emulsion with pharmaceutical use comprising a water-soluble phase and a lipidic phase, comprising at least one surface-active agent based on Polyethyleneglycol and at least one co-surfactant based on polyglycerol.

[0012] It has now been found, and that is what constitutes the subject of the present invention, that it is possible to prepare chemically and physically stable formulations of taxoid for oral administration. The present invention relates to a self-emulsifying formulation for the oral administration of taxoids comprising at least one taxoid and at least one amphiphilic surfactant with hydrophilic character that is preferably Labrasol® (glyceride of PEG and saturated fatty acids).

[0013] In a preferred embodiment of the invention the formulation contains a taxoid up to 200 mg/ml Labrasol®, for example 150 mg taxoid per ml Labrasol®, preferably between 5 and 100 mg taxoid per ml Labrasol®, e.g. 5 mg/ml, 10 mg/ml, 20 mg/ml, 30 mg/ml, 40 mg/ml, 50 mg/ml, 60 mg/ml, 70 mg/ml, 80 mg/ml, 90 mg/ml or 100 mg/ml.

[0014] The taxoid/ Labrasol® formulation may comprise further certain additional additives, the latter may be stabilizing agents, preservatives, agents which make it possible to adjust the viscosity, or agents that can modify, for example, the organoleptic properties.

[0015] In another aspect the invention relates to a self-microemulsifying (SMES) formulation for the oral administration of taxoids comprising at least one taxoid, Cremophor EL® (POE hydrogenated castor oil), at least one co-surfactant and at least one oil.

[0016] The co-surfactant is an amphiphilic surfactant with lipophilic character with an HLB (HLB stands for hydrophilic-lipophilic balance) of less than 10. The co-surfactant is preferably chosen from Peceol® (Glyceryl monooleate), Lauroglycol 129® (PG monolaurate), Capryol 90® (Polyethyleneglycol monocaprylate), Maisine 35-1® (Glyceryl mono-dicaprylate) and Imwitor 988® (Glyceryl mono-dicapryl).

[0017] The oil is preferably a medium-chain triglyceride. The medium-chain triglyceride is preferably Miglyol 812N®.

[0018] The amount of co-surfactant is preferably less than 50 % (weight percent), more preferably less than 40 %, for example 35%, 30%, 25%, 20%, 15%, 10% or 5%. The oil concentration is preferably less than 40 %, more preferably less than 30 %, for example 25%, 20%, 15%, 10% or 5%. In a preferred embodiment of the invention the ratio of surfactant to co-surfactant is 3:1 or higher (i.e. 5:1 or 6:1) and the oil concentration is 20%.

[0019] In a preferred embodiment of the invention the SMES formulation contains a taxoid in an amount comprised between 5 and 50 mg/g, preferably closer to 50 mg/g.

[0020] In a preferred embodiment of the invention the formulation has one of the following compositions:

- Cremophor EL/Maisine/Miglyol 812N or
- Cremophor EL/Lauroglycol 90/Miglyol 812N or
- Cremophor EL/Capryol 90/Miglyol 812N or
- Cremophor EL/Peceol/Miglyol 812N or
- Cremophor EL/Imwitor 988/Miglyol 812N.

[0021] In a preferred embodiment of the invention the formulation has one of the following compositions:

- Cremophor EL/Maisine/Miglyol 812N at 50 mg/g or
- Cremophor EL/Lauroglycol 90/Miglyol 812N at 50 mg/g or
- Cremophor EL/Capryol 90/Miglyol 812N at 50 mg/g or
- Cremophor EL/Peceol/Miglyol 812N at 50 mg/g or

- Cremophor EL/Imwitor 988/Miglyol 812N at 50 mg/g.

[0022] In a preferred embodiment of the invention the SMES contains 50 mg taxoid per g formulation, wherein the formulation comprises 60% Cremophor EL, 20% Imwitor 888 and 20% Miglycol 812N (weight percent).

5 [0023] The taxoid/SMES formulation may comprise further certain additional additives, the latter may be stabilizing agents, preservatives, agents which make it possible to adjust the viscosity, or agents that can modify, for example, the organoleptic properties.

10 [0024] In another aspect the invention relates to a process for preparing said self-emulsifying formulation, wherein there is prepared, where appropriate, the mixture of principal excipients, after heating, if necessary, in the case of the solid or semisolid excipients, and then, if necessary, the mixture with the additional additives, and then the taxoid and stirring is maintained in order to obtain a homogeneous mixture.

[0025] The strategy has been to obtain a formulation able to enhance taxoid solubilisation in aqueous medium by using amphiphilic- and lipid-based formulations able to form a colloidal system (fine emulsion or micellar solution) *in vivo*.

15 Among amphiphilic and lipid-based formulations, 3 categories were identified:

Amphiphilic polymers (micelle or emulsion formation)

Phospholipids (lipidic vesicles formation)

20 SMES (self-microemulsifying systems): oil + surfactant + co-surfactant (microemulsion formation)

25 [0026] After a first selection of proper excipients (in terms of safety and developability), the solubility of taxoids in the excipient was the first screening step for the choice of the excipient and the selection of the prototypes. Then, the prototypes (liquid or semi-solid) were manufactured, and characterized in terms of *in vitro* behaviour in simulated GI media and chemical stability. Finally, the physical properties and stability of the semi-solid prototypes have been investigated.

[0027] Different categories of excipients described in the literature as components of amphiphilic and lipid-based formulations have been tested for the solubility of taxoids:

30

1. Oils (medium-chain triglycerides, fatty acids, ...)

2. Amphiphilic surfactants with hydrophilic character (HLB>10) (PEO sorbitan fatty acids, castor oil ethoxylates, fatty acid ethoxylates.)

35

3. Amphiphilic surfactants with lipophilic character (HLB<10) (glycerides of fatty acids: glyceryl oleate/linoleate, oleoyl macrogol glycerides; derivatives of propylene glycol: PG caprylate/linoleate,)

4. Phospholipids (lecithins)

40

5. Hydrophilic solvents (PEG 400,...)

[0028] All the selected excipients are described as safe for oral administration, and they are developable (alone or as mixture) as pharmaceutical dosage form (soft or hard capsule).

45

[0029] The chemical composition of the selected excipients in liquid form at room temperature, as well as the solubility of taxoid of formula Ib, are reported in table 1 below.

50

55

Table 1: Solubility data of a taxoid of formula Ib in liquid excipients

Commercial name	Chemical description	Solubility (mg/g)
Medium-chain triglycerides		
Miglyol 812N	caprylic/capric triglyceride	65
Soybean oil	glycerides (linoleic acid 50-57%)	16
Amphiphilic surfactants with lipophilic character (HLB <10)		
Crossential O94	Oleic acid	37
Labrafil M1944 CS	oleyl macrogol-6-glycerides	52
Edenor C8 98-100	Caprylic acid	138
Plurol diisostearic		23
Peceol	Glyceryl monooleate	106
Lauroglycol 129	PG monolaurate	129
Capryol 90	Polyethyleneglycol monocaprylate	281
Maisine 35-1	Glyceryl linoleate	129
Plurol oleic CC497	Polyglyceryl 6 oleate	42

Amphiphilic surfactants with hydrophilic character (HLB>10)		
PS 80 VG	POE monooleate	144
PS 80 VG pH 6	POE monooleate	135
Cremophor EL	POE hydrogenated castor oil	94
Labrasol	Caprylocaproyl macrogol-8 glycerides	244
Solvents, cosolvents		
Ethanol		250
HP β cyclodextrin		0.28
Transcutol	Diethylene glycol monoethyl ether	197
PEG 400	polyethylene glycol 400	121
Phospholipids		
Phosal 50 SA	Phosphatidylcholine 50 \pm 3% in alcohol, safflower oil, glyceryl stearate, coconut oil and ascorbyl palmitate	97
Phosal 75 SA	Phosphatidylcholine 75 \pm 3% in alcohol, safflower oil, glyceryl stearate, coconut oil and ascorbyl palmitate	122
Phosal 50 PG	Phosphatidylcholine \geq 50% in propylene glycol	27

[0030] The following table 2 reports the chemical composition of the selected excipients in semi-solid form at room temperature, as well as the solubility of a taxoid of formula Ib. Excipients had been previously melted up to 70°C for drug dissolution.

Table 2: Solubility data in semi-solid excipients (at the melted state) and solid excipients

Commercial name	Chemical description	solubility (mg/g)
Amphiphilic surfactants with lipophilic character (HLB <10)		
Imwitor 988	Glyceryl mono-dicaprylate	283
Hydrophilic surfactants and amphiphilic surfactants with hydrophilic character (HLB >10)		
PEG 4000	polyethylene glycol 1500	>50*
Myrj 45	POE stearate	128
Phospholipids		
Phospholipon 90H	Phosphatidylcholine 93%	Not done

[0031] The solubility of taxoid of formula Ib at room temperature has been determined by X ray diffraction.

[0032] Taking into account the solubility of a taxoid of formula Ib, for the 3 categories of drug delivery systems the following excipients were retained:

Phosal 75SA and Phospholipon 90H for lipidic vesicle formation

Labrasol for emulsion formation

Microemulsion formation: as surfactant Myrj 45, PS80, Cremophor EL, Labrasol; as co-surfactant: Maisine, Capryol 90, Peceol, Lauroglycol 90, Imwitor 988; as oil: Miglyol 812N, Edenor.

[0033] For the first 2 categories, the excipients were formulated as binary systems with the drug, at the following concentrations:

- Phosal 75SA (solution): 100 mg/g formulation
- Phospholipon 90H (solid powder): 50, 100 mg/g formulation
- Labrasol (solution): 50, 100, 200 mg/g formulation

[0034] For the SMES category (3-components system), a first screening of the excipients as oil, surfactant (HLB >10) and co-surfactant (HLB <10), combined together at different ratios without the presence of the active, was necessary for identifying the formulations able to form a microemulsion (droplet size <30 nm) after infinite dilution with water. With this screening the following SMES were identified:

- Cremophor EL/Maisine/Miglyol 812N at 50 mg/g
- Cremophor EL/Lauroglycol 90/Miglyol 812N at 50 mg/g
- Cremophor EL/Capryol 90/Miglyol 812N at 50 mg/g
- Cremophor EL/Peceol/Miglyol 812N at 50 mg/g
- Cremophor EL/Imwitor 988/Miglyol 812N at 50 mg/g

[0035] The ratio between the excipients in the retained formulations was as follow: ratio surfactant to co-surfactant 3:1 and with oil concentration of 20%.

[0036] It is understood that the dosage may vary according to the degree or the nature of the condition to be treated. Thus, the quantity of active product in a composition according to the invention will be determined such that a suitable dosage can be prescribed. As a result, the quantity of taxoids varies as a function of its solubility in the mixture and also as a function of the appropriate dosage for the treatment of patients. Preferably, care should be taken not to load more than 10% w/w of taxoid drug so as to avoid microemulsion destabilization to occur.

[0037] It is understood that, to choose the most appropriate daily dosage in humans, there should be taken into account the weight of the patient, his general state of health, his age and all factors which may influence the efficacy of the treatment. Preferably, the compositions are prepared such that a unit dose contains from 0.1 to 50 mg of active product.

[0038] In the alternative, where a second active ingredient is introduced, the compositions may comprise 0.2 to 50 mg. However, this quantity may optionally be lower and may vary from 0.2 to 10 mg.

[0039] When the composition further comprises certain additional additives, the latter may be stabilizing agents, preservatives, agents which make it possible to adjust the viscosity, or agents that can modify, for example, the organoleptic properties.

[0040] The stabilizing agents may be, for example, antioxidants chosen in particular from α -tocopherol, ascorbyl palmitate, BHT (butyl hydroxytoluene), BHA (butyl hydroxyanisole), propyl gallate or malic acid for example.

[0041] The preservatives may, by way of example, be chosen from sodium metabisulfite, propylene glycol, ethanol or glycerin.

[0042] Among the agents capable of adjusting the viscosity, there may be mentioned, for example, lecithins, phospholipids, propylene glycol alginate, sodium alginate or glycerin.

[0043] The agents capable of modifying the organoleptic properties of the composition are, by way of example, malic acid, fumaric acid, glycerin, vanillin or menthol.

[0044] When such additives are used, the latter may constitute from 0.001% to 5% by weight of the total composition.

[0044] According to the invention, the pharmaceutical composition may be obtained by mixing, where appropriate, the principal excipients (after heating if necessary, in the case of solid or semisolid excipients), and then, if necessary, mixing with the additional additives, followed by the addition of the taxoid and maintaining stirred in order to obtain a homogeneous mixture.

[0045] The compositions according to the invention may be provided in the liquid, state.

[0046] They are particularly suitable for presentation in the form of hard gelatin capsules or soft gelatin capsules, or in the form of an oral solution.

[0047] The compositions according to the invention are particularly advantageous because of their good stability, both physically and chemically, and the enhancement of the bioavailability which they offer upon oral administration of taxoids.

[0048] The following examples, given without limitation, illustrate formulations according to the present invention.

Figures

[0049]

Figure 1: Taxoid of formula Ib release profile of different formulations at 100 mg/g in simulated gastric medium

Figure 2: Taxoid of formula Ib release profile of self-microemulsifying system (SMES) at 50 mg/g in simulated gastric medium

Figure 3: Particle size of Taxoid of formula Ib formulations in simulated gastric medium

Figure 4: Particle size of Taxoid of formula Ib formulations leading to droplets <50 nm in simulated gastric medium

Figure 5: Taxoid of formula Ib - PK profiles with the PS80 formulation

Figure 6: Taxoid of formula Ib - PK profiles with the SMES formulation

Figure 7: Taxoid of formula Ib - PK profiles of nanocrystals of Taxoid of formula Ib

Figure 8: Taxoid of formula Ib - PK profiles of the 3 formulations in dog no 1

Figure 9: Taxoid of formula Ib - PK profiles of the 3 formulations in dog no 2

Figure 10: Taxoid of formula Ib - PK profiles of the 3 formulations in dog no 3

5 Figure 11: Taxoid of formula Ib - Comparison of plasma radioactivity Cmax of different formulations in Beagle dogs.

Figure 12: Taxoid of formula Ib - Comparison of plasma radioactivity AUC of different formulations in Beagle dogs.

Examples

10

Example 1: Preparation of Prototypes

1.1 Materials

15 [0050]

- Taxoid of formula Ib
- Miglyol 812N (Condea Vista Company, Cranford, NJ, USA)
- 20 • Labrasol (Gattefossé, Saint Priest, F)
- Cremophor EL (BASF AG, Ludwigshafen, DE)
- 25 • Capryol 90 (Gattefossé, Saint Priest, F)
- Lauroglycol 90 (Gattefossé, Saint Priest, F)
- Peceol (Gattefossé, Saint Priest, F)
- 30 • Maisine 35-1 (Gattefossé, Saint Priest, F)
- Imwitor 988 (Condea Vista Company, Cranford, NJ, USA)
- 35 • Phosal 75SA (Nattermann, Cologne, DE)
- Phospholipon 90H (Nattermann, Cologne, DE)
- PS80 VG DF (Seppic, Paris, France)
- 40

1.2 Preparation of the solutions

[0051] The weighed drug was dispersed in the excipient, and then maintained under mechanical stirring until complete dissolution (approximately 3-5 hours). In the case of the SMES formulations, the drug was dissolved in the mix
45 of the 3 excipients previously homogenized together.

1.3 Preparation of the solid dispersions.

[0052] The drug and the excipient (Phospholipon 90H) were dispersed in absolute ethanol (0.1 g drug, 0.9 g excipient, 50 6 g; ethanol) in a balloon reactor, then heated at 50°C until dissolution. The solvent evaporation by Rotavap (150-200 mbar, 1h30, 110 rpm rotation) led to the formation of a fluffy white powder.

1.4 Chemical stability

55 [0053] The chemical stability of the different formulations is a key parameter. Prototypes were stored in bulk (glass vial) for up to 3 months at +5°C ($\pm 3^\circ\text{C}$), 25°C ($\pm 2^\circ\text{C}$) and 30°C ($\pm 2^\circ\text{C}$) under 60% ($\pm 5\%$) relative humidity (RH) and 40°C ($\pm 2^\circ\text{C}$) under 75% ($\pm 5\%$) RH.

The stability was evaluated by mean of the potency determined by HPLC, as well as evaluation of relative substances.

The prototypes analysed for drug dosage and stability studies are showed in the table below.

Table 3:

Prototypes of taxoid of formula Ib formulations for stability study	
PROTOTYPE	DRUG CONCENTRATION mg/g formulation
PS 80	100
Capryol 90	250
Labrasol	100
Labrasol	200
Phosal 75 SA	100
CremophorEL-Miglyol 812N-Peceol	50
CremophorEL-Miglyol 812N -Maisine	50
CremophorEL-Miglyol 812N-Lauroglycol 90	50
Cremophor EL-Miglyol 812N-Capryol 90	50
Cremophor EL-Miglyol 812N-Irwitor 988	50
Phospholipon 90 H	50
Phospholipon 90 H	100

[0054] All the formulations are stable 3 months at 40°C under 75% RH, except the SMES formulations. Indeed, the SMES are stable 1 month at 25°C, whereas at 40°C the impurity taxoid of formula Ib (hydrolysis) appears (1.15-3.88% at t_1 month, depending on the nature of the co-surfactant). The 3 months analysis of the sample allowed to evaluate if this impurity increase was critical: after 3 months, an increase of taxoid of formula Ib impurity content was noticed. The SMES is stable at 5°C during 7 months.

Example 2: in vitro behaviour in simulated gi media

[0055] Release profiles after incubation in simulated gi media

Composition of the simulated fluids

[0056] The following simulated media were selected for the present experiment:

- Gastric medium USP, pH 1.2
- Fasted intestinal medium, pH 6.8 (ref. Dressman et al., Pharm. Res., 1998)
- Fed intestinal medium, pH 5 (ref. Dressman et al., Pharm. Res., 1998)

Table 4:

Composition of the simulated gastro-intestinal media		
Gastric medium (G)		
Sodium chloride	2 g	
Hydrogen chloride 1N	100 ml approximately	
Demineralised water	qsp 1000 ml	

Table 4: (continued)

Composition of the simulated gastro-intestinal media		
Fasted intestinal medium (Fassif)		For 500 ml
Potassium hydrogenophosphate	0.029 M	1.97 g
Sodium hydroxide	qs pH 6.8	qs pH 6.8
Sodium Taurocholate	5 mM	1.34 g
Lecithin (Phospholipon 90G)	1.5 mM	0.58 g
Potassium chloride	0.22 M	8.2 g
Demineralised water	qsp 11	qsp 500 ml
Fed intestinal medium (Fessif)		For 500 ml
Acetic acid	0.144 M	4.33 g
Sodium hydroxide	qs pH 5	qs pH 5
Sodium Taurocholate	15 mM	4.03 g
Lecithin (Phospholipon 90G)	4 mM	1.55 g
Potassium chloride	0.19 M	7.08 g
Demineralised water	qsp 11	qsp 500 ml

2.1 Experimental conditions

[0057] In a first step of experiments, the formulations (100 mg drug/g formulation, 500 mg formulation in a hard gelatin capsule) were diluted 1:500 in the gastric medium (1 capsule/250 mL), then incubated 2 hours at 37°C under stirring (50 rpm) in a USP standard dissolution apparatus.

The same experiment has been carried out in gastric medium with 2 capsules loaded with less concentrated formulations (50 mg drug/g formulation), in order to study the effect of the drug/excipient and excipient/medium ratio on the release profile.

In a second step of experiments, a first incubation of 1 hour in gastric medium was followed by 2 hours incubation in fasted intestinal or fed intestinal medium, in order to simulate the gastric emptying process.

[0058] Samples were taken after 5-15-30-60 min and 2h. The drug concentration was determined by HPLC after centrifugation (6000 rpm, 10 min). Homogeneity of the medium was evaluated by sampling bottom, medium and top of the vessel.

2.2 Results

[0059] Drug release profiles in gastric medium of formulations at 100 mg/g are shown in the figure 1.

The profile obtained with formulation data from Phosal is not very representative, since these formulations led to the formation of a very heterogeneous mixture after incubation. The Labrasol formulation led to the formation of a very homogeneous emulsion with the medium, despite the low amount of drug recovered after centrifugation (see release profile), suggesting that for a coarse emulsion the centrifugation (determining the collapse of the emulsion) could sub-estimate its *in vitro* performance. The experiment with Phospholipon 90H was stopped (no data collection) since the powder floating did not allow the formation of a homogeneous suspension.

[0060] The *in vitro* profiles of all the 5 self-microemulsifying systems (SMES) tested exhibited a 100% "release" in a few minutes (figure 2). However, the fact that the centrifugation does not allow to separate the aqueous and oily phase of the SMES means that the SMES is still finely dispersed in the aqueous phase (gastric medium) after centrifugation, and the drug is still solubilised into the tiny microemulsion droplets. Nevertheless, the SMES system is definitely extremely interesting, even if the chemical stability could be an issue (effect of the presence of hygroscopic surfactant or co-surfactant on the drug chemical stability to investigate).

Example 3: particle size analysis after incubation in gastric medium (USP)

[0061] The aim of this part of the study was to evaluate, by particle size measurement, the colloidal stability and the self-emulsifying properties of the emulsion/microemulsion/micellar solution of taxoid of formula Ib formulations after incubation in the gastric medium.

3.1 Experimental conditions

[0062] The formulations (concentration 100 mg drug/g formulation, 100 mg formulation) were diluted 1:500 in the gastric medium (50 mL), then incubated 2 hours at 37°C under mechanical stirring (300 rpm).

5 The sample was diluted immediately with water for size measurement or filtered onto 2 µm if necessary. The filtration allowed to retain oil droplets >2 µm, as well as drug crystals >2 µm, in order to allow the particle size measurement by QELS (quasi-elastic light scattering) (Nanosizer N4+, Beckmann-Coulter).

3.2 Results

10

[0063] As shown in the figures 3 and 4, a particle size <50 nm was obtained only in the case of the formulations with active concentration of 50 mg/g: the 5 microemulsions (nevertheless their composition).

The results suggest using the formulations able to form small and monodisperse droplets in gastric medium in order to have a better performance *in vivo*. Further experiments in simulated intestinal media should be performed in order

15

3.3 Preliminary conclusions on the evaluation of taxoid of formula Ib formulations

20 [0064] All the results concerning the *in vitro* behaviour in simulated GI fluids of the formulations for oral administration of taxoid of formula Ib, as well as the chemical stability in accelerated conditions, are summarized in the tables below.

Table 5:

Summary of the <i>in vitro</i> behaviour of the formulations at 50 mg/g					
Formulation	Chemical Stability	Droplet size <i>in vitro</i> (2h at 37°C in gastric medium)	Homogeneity <i>in vitro</i> (2h at 37°C in gastric medium)	% released drug <i>in vitro</i> after 2h in gastric medium)	% released drug <i>in vitro</i> after 1h gastric + 2h Fassif
Labrasol	Not done	Not done	Good	2%	23%
30 SMES (5)	7 months at 5°C	<30 nm	Good	>90%	100%

35 [0065] Since the *in vitro* behaviour of the 5 SMES is almost identical, the recommended SMES for further evaluation is the one containing Imwitor 988 as co-surfactant: indeed, this excipient is described as able to prevent the lipolysis inhibition that generally occurs with hydrophilic surfactants (such as Cremophor) and should allow the digestion of the lipid (Miglyol) for drug release and absorption. Since the absorption of taxoid of formula Ib is not a critical step, a delayed lipolysis (to enhance the uptake of intact droplets by the lymphatic pathway) is not desirable.

Table 6:

Summary of the <i>in vitro</i> behaviour of the formulations at 100 mg/g					
Formulation	Chemical Stability	Droplet size <i>in vitro</i> (2h at 37°C in gastric medium)	Homogeneity <i>in vitro</i> (2h at 37°C in gastric medium)	% released drug <i>in vitro</i> after 2h in gastric medium)	% released drug <i>in vitro</i> after 1h gastric + 2h Fassif
45 Labrasol	>3 months at 40°C/75%RH	>1 µm	Good	1-11%	5-14%
50 SMES (5)	Not done	>1 µm (no microemulsion)	Not done	Not done	Not done

[0066] At 100 mg/g, only Labrasol formulation exhibited a promising behaviour (in terms of release profile and droplet size).

55

4. Conclusions and further studies

[0067]

Table 7: Comparative properties of the recommended formulations according to the selection criteria

Criteria	FORMULATION	
	SMES	Labrasol
Safety excipients	Yes	Yes
Registrability excipients	Yes	Yes
Developpability/registrability formulation	Yes	Yes
Conc.>50 mg/g	Yes (up to 50)	Yes (up to 200)
Chemical Stability t _{3 months}	5°C t _{7 months}	40°C/75%RH
Solubilisation in GI media	Very good	Good
Fine droplet size (GI media)	Yes (25 nm)	No (>1 µm)
Physical Stability t _{1 months}	Not determined	Not determined

Example 5: Taxoid of formula Ib - COMPARISON OF DIFFERENT FORMULATIONS IN BEAGLE DOGS

[0068] Three male Beagle dogs were tested with a dose of 0.5 mg/kg with the following formulations: Polysorbate 80; Self-microemulsifying system (SMES) at 50 mg/g (composition Cremophor EL 60%, Imwitor 988 20%, Miglyol 812N 20%); Nanocrystal suspension of ¹⁴C-taxoid of formula Ib. The Plasma radioactivity profiles were determined by LSC.

Results:

[0069] The plasma radioactivity concentration in the Beagle dogs after a single oral administration of C-14-taxoid of formula Ib at 0,5 mg/kg of a PS 80 formulation was determined (figure 5).

[0070] The plasma radioactivity concentration in the Beagle dogs after a single oral administration of C-14-taxoid of formula Ib at 0,5 mg/kg of the SMES formulation was determined (figure 6).

[0071] The plasma radioactivity concentration in the Beagle dogs after a single oral administration of C-14-taxoid of formula Ib at 0,5 mg/kg of a nanocrystal formulation was determined (figure 7).

[0072] The plasma radioactivity concentration in the Beagle dog N°1 after a single oral administration of C-14-taxoid of formula Ib at 0.5 mg/kg was determined (figure 8).

[0073] The plasma radioactivity concentration in the Beagle dog N°2 after a single oral administration of C-14-taxoid of formula Ib at 0.5 mg/kg was determined (figure 9).

[0074] The plasma radioactivity concentration in the Beagle dog N°3 after a single oral administration of C-14-taxoid of formula Ib at 0.5 mg/kg was determined (figure 10).

[0075] The maximum plasma radioactivity concentrations (C_{max}) in the beagle dogs after a single oral administration of C-14-taxoid of formula Ib at 0.5 mg/kg were determined (figure 11). No difference was demonstrated in plasma radioactivity C_{max} for PS80 and SMES formulations. Significant differences were demonstrated for PS80 or SMES and nanocrystal formulations.

5 [0076] The² plasma radioactivity exposure (AUC (0-48 h)) in the Beagle dogs after a single oral administration of C-14-taxoid of formula Ib at 0.5 mg/kg was determined (figure 12). No difference was demonstrated in plasma radioactivity AUC for PS80 and SMES formulations. PS80 or SMES means AUC were 1.6-fold higher than that of nanocrystal.

[0077] The results can be summarized as follows:

- 10 • Rapid absorption of radioactivity (t_{max} 0.5-2h) and low variability of radioactivity concentrations (C.V. <11% for C_{max}) for PS80 and self-microemulsifying formulations were observed.
- Rapid to slow absorption (t_{max} 0.5-4h) of radioactivity and high variability of radioactivity concentrations (C.V. 49% for C_{max}) for nanocrystal formulation were observed.
- No difference was demonstrated in plasma radioactivity C_{max} and AUC for PS80 and self-microemulsifying for-
- 15 • Plasma radioactivity mean C_{max} and AUC for PS80 or self-microemulsifying formulations are at least 1.6-fold higher than that of nanocrystal.

20 Claims

1. Self-emulsifying formulation for the oral administration of taxoids comprising at least one taxoid and at least one amphiphilic surfactant that is Labrasol®.
- 25 2. Self-emulsifying formulation as claimed in claim 1, wherein the formulation contains up to 200 mg taxoid per ml Labrasol®
3. Self-emulsifying formulation as claimed in claims 1 or 2, wherein the formulation contains between 50 and 100 mg taxoid per ml Labrasol®.
- 30 4. Self-emulsifying formulation for the oral administration of taxoids comprising at least one taxoid and at least one amphiphilic surfactant which is Labrasol® and at least one additional additive chosen from stabilizing agents, preservatives, agents which make it possible to adjust the viscosity, or agents that can modify the organoleptic properties.
- 35 5. Self-microemulsifying formulation for the oral administration of taxoids comprising at least one taxoid, at least one co-surfactant, at least one oil and a surfactant (Cremophor EL®).
- 40 6. Self-microemulsifying formulation for the oral administration of taxoids comprising at least one taxoid, at least one co-surfactant, at least one oil, one surfactant (Cremophor EL®) and at least one additional additive chosen from stabilizing agents, preservatives, agents which make it possible to adjust the viscosity, or agents that can modify the organoleptic properties.
- 45 7. Self-microemulsifying formulation as claimed in claims 5 or 6, wherein the co-surfactant is an amphiphilic surfactant with lipophilic character with an HLB of less than 10.
8. Self-microemulsifying formulation as claimed in claims 5 to 7, wherein the co-surfactant is chosen from Peceol®, Lauroglycol 129®, Capryol 90®, Maisine 35-1® and Imwitor 988®.
- 50 9. Self-microemulsifying formulation as claimed in claims 5 to 8, wherein the oil is Miglyol 812N®.
10. Self-microemulsifying formulation as claimed in claims 5 to 9, wherein the amount of co-surfactant is less than 50 % (weight percent).
- 55 11. Self-microemulsifying formulation as claimed in claims 5 to 10, wherein the oil concentration is less than 40 %.
12. Self-microemulsifying formulation as claimed in claims 5 to 11, wherein the ratio of surfactant to co-surfactant is 3:1 and the oil concentration is 20%.

13. Self-microemulsifying formulation as claimed in claims 5 to 12, wherein the taxoid concentration is not over 10% w/w.

14. Self-microemulsifying formulation as claimed in claim 13, wherein the taxoid concentration is from 1 to 50 mg/g.

15. Self-microemulsifying formulation as claimed in claims 5 to 14, wherein the formulation comprises 60% Cremophor EL, 20% Imwitor 888 and 20% Miglycol 812N (weight percent).

16. A process for preparing a formulation as claimed in claims 1 to 6, wherein there is prepared, where appropriate, the mixture of principal excipients, after heating, if necessary, in the case of the solid or semisolid excipients, and then, if necessary, the mixture with the additional additives, and then the taxoid and stirring is maintained in order to obtain a homogeneous mixture.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11





Figure 12



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 03 29 1798

DOCUMENTS CONSIDERED TO BE RELEVANT			Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages			
D,X	WO 99 49848 A (RTP PHARMA INC) 7 October 1999 (1999-10-07)	1,2,4,16	A61K47/44 A61K9/107 A61K47/14 A61K31/337	
Y	* examples 1-4 *	3		
	* page 3, line 28 - line 31 *			
	* page 4, line 16 - page 5, line 11 *			
X	* page 7, line 18 - line 23 *	5-7, 9-14,16		
	* examples 1-5 *			
	* claims 1-21 *			
	* page 4, line 16 - page 5, line 11 *			
	* page 6, line 11 - page 7, line 8 *			
X	WO 00 03753 A (TALLAVAJHALA SIVA NARAYAN ; EM IND INC (US))	1,2,4		
Y	27 January 2000 (2000-01-27)	3		
	* example 11 *			
X	WO 02 087563 A (ANGIOTECH PHARM INC ; LIGGINS RICHARD T (CA); TOLEIKIS PHILIP M (CA);) 7 November 2002 (2002-11-07)	1,2,4,16		
Y	* example 4 *	3		
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)	
X	WO 03 045357 A (TRANSFORM PHARMACEUTICALS INC ; CHEN HONGMING (US); ZHANG ZHONG (US);) 5 June 2003 (2003-06-05)	1,2,4	A61K	
Y	* abstract *	3		
	* claims 1-3,40,53,55 *			
X	US 6 267 985 B1 (CHEN FENG-JING ET AL) 31 July 2001 (2001-07-31)	5-7, 9-11,13, 14,16		
	* example 46 *			
	* claim 1 *			
	* table 1 *			
	* table 6 *	15		
X	* column 8, line 42 - line 67 *	5-16		
A				
	-/--			
The present search report has been drawn up for all claims				
Place of search Munich		Date of completion of the search 14 January 2004	Examiner Giacobbe, S	
CATEGORY OF CITED DOCUMENTS			T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document				

EPO FORM 1503 (03.02.2003) (P04001)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 03 29 1798

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	"Fiedler Lexicon der Hilfstoffe" 2002, EDITIO CANTOR VERLAG, AULENDORF, XP002257694 * page 472, column 1 - page 473, column 2 * * page 995, column 1 - column 2 *	1-4,16	
A	US 5 698 582 A (BASTART JEAN-PIERRE ET AL) 16 December 1997 (1997-12-16) * example 9 *	5-16	
A	WO 01/001960 A (LIPOCINE INC) 11 January 2001 (2001-01-11) * claims 1,2,5 * * page 5, line 21 - line 22 *	5-16	
A	WO 98/57630 A (THISSEN L T B LAB ; LOUVET FREDDY (BE); GECZY JOSZEF (BE)) 23 December 1998 (1998-12-23) * the whole document *	5-16	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 14 January 2004	Examiner Giacobbe, S
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : technological background O : non-written disclosure P : intermediate document & : member of the same patent family, corresponding document	

EPO FORM 1503 03.02 (Pst/Cst)



European Patent
Office

Application Number

EP 03 29 1798

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):

☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

☒ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.

☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.

☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:

☐ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:



European Patent
Office

LACK OF UNITY OF INVENTION
SHEET B

Application Number

EP 03 29 1798

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1-4; 16 (in part)

Self-emulsifying oral formulation of a taxoid compound
comprising Labrasol (caprylocaproyl macrogolglyceride)

2. claims: 5-15; 16 (in part)

Self- microemulsifying oral formulation of a taxoid compound
comprising at least one surfactant, one oil and Cremophor EL

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 03 29 1798

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-01-2004

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9949848	A	07-10-1999	AU 756752 B2	23-01-2003
			AU 3377099 A	18-10-1999
			CA 2326485 A1	07-10-1999
			CN 1303269 T	11-07-2001
			EP 1067908 A1	17-01-2001
			JP 2002509877 T	02-04-2002
			SE 0003449 A	23-11-2000
			TW 546152 B	11-08-2003
			WO 9949848 A1	07-10-1999
WO 0003753	A	27-01-2000	AU 4989299 A	07-02-2000
			CA 2302735 A1	27-01-2000
			CN 1273526 T	15-11-2000
			DE 1015046 T1	08-02-2001
			EP 1015046 A2	05-07-2000
			JP 2002520377 T	09-07-2002
			WO 0003753 A2	27-01-2000
			ZA 200001010 A	16-10-2000
WO 02087563	A	07-11-2002	WO 02087563 A2	07-11-2002
			US 2002192280 A1	19-12-2002
			US 2003157161 A1	21-08-2003
WO 03045357	A	05-06-2003	WO 03045357 A1	05-06-2003
US 6267985	B1	31-07-2001	AU 5313100 A	22-01-2001
			CA 2375083 A1	11-01-2001
			EP 1194120 A1	10-04-2002
			JP 2003503440 T	28-01-2003
			NZ 516521 A	28-11-2003
			WO 0101960 A1	11-01-2001
			US 2003077297 A1	24-04-2003
			US 2003104048 A1	05-06-2003
			US 2003235595 A1	25-12-2003
			US 2003236236 A1	25-12-2003
			US 2002032171 A1	14-03-2002
US 5698582	A	16-12-1997	FR 2678833 A1	15-01-1993
			US 5714512 A	03-02-1998
			AT 161193 T	15-01-1998
			AT 147992 T	15-02-1997
			AU 666859 B2	29-02-1996
			AU 2278792 A	11-02-1993
			CA 2102777 A1	09-01-1993
			CA 2102778 A1	09-01-1993
			CZ 280965 B6	15-05-1996

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 03 29 1798

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-01-2004

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5698582 A		CZ 9400032 A3	15-02-1995
		DE 69217056 D1	06-03-1997
		DE 69217056 T2	05-06-1997
		DE 69223624 D1	29-01-1998
		DE 69223624 T2	23-04-1998
		DK 593601 T3	09-02-1998
		DK 593656 T3	10-02-1997
		EP 0522936 A1	13-01-1993
		EP 0522937 A1	13-01-1993
		EP 0593601 A1	27-04-1994
		EP 0593656 A1	27-04-1994
		ES 2110003 T3	01-02-1998
		ES 2096091 T3	01-03-1997
		FI 940073 A	07-01-1994
		FI 940074 A	07-01-1994
		WO 9300928 A1	21-01-1993
		WO 9300929 A1	21-01-1993
		GR 3022355 T3	30-04-1997
		GR 3025714 T3	31-03-1998
		HK 1006207 A1	12-02-1999
		HU 65960 A2	29-08-1994
		IE 922212 A1	13-01-1993
		IE 922213 A1	13-01-1993
		JP 2595458 B2	02-04-1997
		JP 6507913 T	08-09-1994
		JP 2618596 B2	11-06-1997
		JP 6507914 T	08-09-1994
		KR 136722 B1	25-04-1998
		MX 9203959 A1	01-01-1993
		MX 9203960 A1	01-01-1993
		NO 934609 A	14-12-1993
		NO 934610 A	14-12-1993
		PL 169372 B1	31-07-1996
		RU 2134123 C1	10-08-1999
		SG 80541 A1	22-05-2001
		SK 1594 A3	05-10-1994
		TW 495362 B	21-07-2002
		US 5750561 A	12-05-1998
		US 5403858 A	04-04-1995
WO 0101960 A	11-01-2001	US 6267985 B1	31-07-2001
		AU 5313100 A	22-01-2001
		CA 2375083 A1	11-01-2001
		EP 1194120 A1	10-04-2002
		JP 2003503440 T	28-01-2003
		NZ 516521 A	28-11-2003

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 03 29 1798

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-01-2004

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0101960	A		WO 0101960 A1	11-01-2001
			US 2003077297 A1	24-04-2003
			US 2003104048 A1	05-06-2003
			US 2003235595 A1	25-12-2003
			US 2003236236 A1	25-12-2003
			US 2002032171 A1	14-03-2002
WO 9857630	A	23-12-1998	BE 1011216 A3	01-06-1999
			AU 7632198 A	04-01-1999
			WO 9857630 A1	23-12-1998
			ZA 9804832 A	04-01-1999

EPO FORM P0489

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82